GSK and Laboratorios Phoenix - Top 5 Emerging Market Deals

Who: GlaxoSmithKline
With: Laboratorios Phoenix
Where: Argentina

Deal Size: $253 million

Details: Earlier this year GlaxoSmithKline CEO Andrew Witty declared his company's intentions to grow beyond 'white pills and western markets.' The drugmaker has certainly done that, snapping up emerging market drug companies around the globe. It's biggest acquisition in the last 12 months was Argentinian company Laboratorios Phoenix. The drugmaker boasts a pipeline of branded generic pharmaceutical products covering therapeutic areas including cardiovascular, gastroenterology, metabolic and urology, as well as a manufacturing facility near Buenos Aires and an established primary care sales force.

According to IMS Argentina is the eighth largest emerging market, valued at $3 billion and growing at a rate of 22 percent annually. Phoenix reported sales of approximately $110 million in 2009 and it is currently ranked number eight in the Argentine pharmaceutical market. Prior to the acquisition GSK was in 11th place in Argentina; combined, the two companies are the third largest pharma company in the country.

GSK and Laboratorios Phoenix - Top 5 Emerging Market Deals
Read more on

Suggested Articles

J&J's talc woes deepened Friday after the FDA turned up "sub-trace" levels of asbestos one bottle of the company's baby powder,…

Another major drugmaker is recalling in the U.K. 10 batches of its Zantac generics because they contain a possible carcinogen.

With diagnosis rates on the rise, Pfizer's Vyndaqel franchise could collect $157 million in 2019 U.S. sales, well above consensus, SVB Leerink says.